QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
NASDAQ:CTIC

CTI BioPharma - CTIC Stock Forecast, Price & News

$5.51
-0.21 (-3.67%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.45
$5.77
50-Day Range
$5.24
$6.02
52-Week Range
$1.82
$7.80
Volume
2.73 million shs
Average Volume
2.99 million shs
Market Capitalization
$699.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
99.6% Upside
$11.00 Price Target
Short Interest
Bearish
11.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.08mentions of CTI BioPharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.29 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.72) to $0.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

662nd out of 1,049 stocks

Pharmaceutical Preparations Industry

338th out of 514 stocks


CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

CTIC.OQ - | Stock Price & Latest News | Reuters
CTI BioPharma Corp. (NASDAQ:CTIC) EVP Sells $600,000.00 in Stock
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
CTI BioPharma (NASDAQ:CTIC) Stock Rating Lowered by StockNews.com
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
CTI BioPharma to Present at Upcoming November Conferences
CTI BioPharma: Q3 Earnings Snapshot
CTI BioPharma's VONJO May Be Coming Of Age
Analyst Ratings for CTI BioPharma
Why CTI BioPharma Stock Crushed the Market Today
Where CTI BioPharma Stands With Analysts
Why CTI BioPharma Stock Withered on Wednesday
Analyst Ratings: What Are They?
What 4 Analyst Ratings Have To Say About CTI BioPharma
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Company Calendar

Last Earnings
11/07/2022
Today
1/30/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
22
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+99.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-97,910,000.00
Pretax Margin
-341.77%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.04 per share

Miscellaneous

Free Float
113,951,000
Market Cap
$699.16 million
Optionable
Optionable
Beta
0.85

Social Links


Key Executives

  • Adam R. CraigAdam R. Craig
    President, CEO, Chief Medical Officer & Director
  • David H. Kirske
    Chief Financial Officer & Executive Vice President
  • Jim Fong
    Chief Commercial Officer & Executive VP
  • John Volpone
    Senior Vice President-Strategic Operations













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2023?

8 equities research analysts have issued 1 year price objectives for CTI BioPharma's stock. Their CTIC share price forecasts range from $9.00 to $13.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How have CTIC shares performed in 2023?

CTI BioPharma's stock was trading at $6.01 on January 1st, 2023. Since then, CTIC stock has decreased by 5.0% and is now trading at $5.71.
View the best growth stocks for 2023 here
.

When is CTI BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CTIC earnings forecast
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) released its quarterly earnings results on Monday, November, 7th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. The biopharmaceutical company earned $18.24 million during the quarter, compared to analyst estimates of $18.13 million.

When did CTI BioPharma's stock split?

CTI BioPharma shares reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

How do I buy shares of CTI BioPharma?

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $5.71.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $724.54 million. The biopharmaceutical company earns $-97,910,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 1/30/2023 by MarketBeat.com Staff